Try our mobile app

Switch to company model in classical logic    *

General information

Country: CANADA

Sector: Medical Instruments and Supplies

Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Website: bausch.com



Growth: Good revenue growth rate 17.9%, there is acceleration compared to average historical growth rates 9.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +6.4%. On average the margin is decreasing unsteadily. Gross margin is high, +61.4%. In the last quarter the company beat the estimated EPS, 0.0%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 1.8% higher than minimum and 35.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.2x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: BLCO
Share price, USD:  (-1.9%)13.6
year average price 16.97  


year start price 17.50 2023-05-06

max close price 20.99 2023-07-13

min close price 13.60 2024-05-03

current price 13.60 2024-05-04
Common stocks: 342 333 528

Dividend Yield:  0.0%
EV / LTM EBITDA: 17.1x
EV / EBITDA annualized: 12.5x
Last revenue growth (y/y):  17.9%
Last growth of EBITDA (y/y):  9.4%
Historical revenue growth:  9.4%
Historical growth of EBITDA:  -19.2%
EV / Sales: 1.1x
Margin (EBITDA LTM / Revenue): 6.4%
Fundamental value created in LTM:
Market Cap ($m): 4 656
Net Debt ($m): 0
EV (Enterprise Value): 4 656
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-15Business Wire

Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1

2024-03-25Zacks Investment Research

All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy

2024-03-20Zacks Investment Research

Surging Earnings Estimates Signal Upside for Bausch + Lomb (BLCO) Stock

2024-02-21Seeking Alpha

Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript

2024-02-21Zacks Investment Research

Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics

2024-02-21Market Watch

Bausch & Lomb's stock soars 11% after earnings beat

2024-02-15Zacks Investment Research

Seeking Clues to Bausch + Lomb (BLCO) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

2024-02-14Zacks Investment Research

Will Bausch + Lomb (BLCO) Beat Estimates Again in Its Next Earnings Report?

2024-02-14Zacks Investment Research

Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Should You Buy?

2023-11-01Seeking Alpha

Bausch + Lomb Corporation (BLCO) Q3 2023 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BLCO BLCO BLCO BLCO BLCO BLCO BLCO
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-01 2024-02-21 2023-11-01 2023-08-02 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-05-01 16:47:31 2024-02-21 16:55:05 2023-11-01 17:03:58 2023-08-02 16:18:05 2023-05-03 17:15:41 2023-02-22 17:15:33 2022-11-02 16:53:38
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 099M 1 173M 1 007M 1 035M 931M 996M 942M
costOfRevenue 498M 461M 392M 417M 372M 420M 372M
grossProfit 601M 712M 615M 618M 559M 576M 570M
grossProfitRatio 0.547 0.607 0.611 0.597 0.600 0.578 0.605
researchAndDevelopmentExpenses 82M 80M 82M 85M 77M 78M 77M
generalAndAdministrativeExpenses 0 108M 0 0 0 0 0
sellingAndMarketingExpenses 0 375M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 504M 483M 418M 417M 418M 386M 381M
otherExpenses 0 -12M -28M -17M 57M 56M 59M
operatingExpenses 586M 643M 547M 558M 552M 520M 517M
costAndExpenses 1 084M 1 104M 939M 975M 924M 940M 889M
interestIncome 3M 3M 4M 5M 3M 3M 2M
interestExpense -99M 99M 76M 58M 50M 47M 35M
depreciationAndAmortization 110M 116M 47M 56M 57M 59M 98M
ebitda 125M 188M 91M 104M 58M 110M 144M
ebitdaratio 0.114 0.160 0.090 0.100 0.062 0.110 0.153
operatingIncome 15M 49M 40M 43M 1 000 000 51M 46M
operatingIncomeRatio 0.014 0.042 0.040 0.042 0.001 0.051 0.049
totalOtherIncomeExpensesNet -105M -30M -31M -26M -56M -53M -27M
incomeBeforeTax -90M -57M -35M -19M -55M -2M 19M
incomeBeforeTaxRatio -0.082 -0.049 -0.035 -0.018 -0.059 -0.002 0.020
incomeTaxExpense 73M -6M 45M 10M 33M -2M 34M
netIncome -167M -54M -84M -32M -88M -1 000 000 -15M
netIncomeRatio -0.152 -0.046 -0.083 -0.031 -0.095 -0.001 -0.016
eps -0.480 -0.150 -0.240 -0.091 -0.250 -0.003 -0.043
epsdiluted -0.480 -0.150 -0.240 -0.091 -0.250 -0.003 -0.043
weightedAverageShsOut 351M 351M 351M 350M 350M 350M 350M
weightedAverageShsOutDil 351M 351M 351M 350M 350M 350M 350M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BLCO BLCO BLCO BLCO BLCO BLCO BLCO
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-01 2024-02-21 2023-11-01 2023-08-02 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-05-01 16:47:31 2024-02-21 16:55:05 2023-11-01 17:03:58 2023-08-02 16:18:05 2023-05-03 17:15:41 2023-02-22 17:15:33 2022-11-02 16:53:38
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 325M 331M 355M 384M 346M 354M 287M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 325M 331M 355M 384M 346M 354M 287M
netReceivables 960M 839M 783M 791M 714M 724M 685M
inventory 1 073M 1 028M 754M 699M 697M 628M 605M
otherCurrentAssets 385M 541M 567M 433M 415M 431M 282M
totalCurrentAssets 2 743M 2 742M 2 464M 2 315M 2 184M 2 137M 1 859M
propertyPlantEquipmentNet 1 397M 1 390M 1 284M 1 294M 1 296M 1 300M 1 222M
goodwill 4 547M 4 575M 4 526M 4 540M 4 522M 4 507M 4 415M
intangibleAssets 3 515M 3 589M 3 662M 2 021M 2 031M 2 058M 2 068M
goodwillAndIntangibleAssets 8 062M 8 164M 8 188M 6 561M 6 553M 6 565M 6 483M
longTermInvestments 19M 19M 12M 0 0 0 0
taxAssets 860M 921M 920M 938M 923M 927M 904M
otherNonCurrentAssets 212M 206M 200M 207M 213M 215M 228M
totalNonCurrentAssets 10 550M 10 700M 10 604M 9 000M 8 985M 9 007M 8 837M
otherAssets 0 0 0 0 0 0 0
totalAssets 13 293M 13 442M 13 068M 11 315M 11 169M 11 144M 10 696M
accountPayables 426M 522M 364M 348M 389M 370M 295M
shortTermDebt 30M 30M 30M 25M 25M 25M 25M
taxPayables 0 0 0 0 0 0 0
deferredRevenue 0 627M 566M 0 0 0 0
otherCurrentLiabilities 1 161M 400M 426M 952M 840M 901M 879M
totalCurrentLiabilities 1 617M 1 579M 1 386M 1 325M 1 254M 1 296M 1 199M
longTermDebt 4 554M 4 532M 4 435M 2 604M 2 508M 2 411M 2 413M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 14M 14M 11M 14M 14M 7M 10M
otherNonCurrentLiabilities 379M 397M 353M 342M 341M 329M 2 382M
totalNonCurrentLiabilities 4 947M 4 943M 4 799M 2 960M 2 863M 2 747M 2 702M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 0 87M 0 0 0 0 0
totalLiabilities 6 564M 6 522M 6 185M 4 285M 4 117M 4 043M 3 901M
preferredStock 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0
retainedEarnings -421M -254M -200M -116M -84M 6M 7M
accumulatedOtherComprehensiveIncomeLoss -1 283M -1 245M -1 317M -1 247M -1 238M -1 258M -1 386M
othertotalStockholdersEquity 8 363M 8 349M 8 334M 8 321M 8 305M 8 285M 8 108M
totalStockholdersEquity 6 659M 6 850M 6 817M 6 958M 6 983M 7 033M 6 729M
totalEquity 6 729M 6 920M 6 883M 7 030M 6 983M 7 033M 6 729M
totalLiabilitiesAndStockholdersEquity 13 293M 13 442M 13 068M 11 315M 11 169M 11 144M 10 630M
minorityInterest 70M 70M 66M 72M 69M 68M 0
totalLiabilitiesAndTotalEquity 13 293M 13 442M 13 068M 11 315M 11 169M 11 144M 10 630M
totalInvestments 19M 19M 12M 0 0 0 0
totalDebt 4 584M 4 562M 4 465M 2 629M 2 533M 2 436M 2 438M
netDebt 4 259M 4 231M 4 110M 2 245M 2 187M 2 082M 2 151M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BLCO BLCO BLCO BLCO BLCO BLCO BLCO
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-01 2024-02-21 2023-11-01 2023-08-02 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-05-01 16:47:31 2024-02-21 16:55:05 2023-11-01 17:03:58 2023-08-02 16:18:05 2023-05-03 17:15:41 2023-02-22 17:15:33 2022-11-02 16:53:38
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -167M -51M -80M -29M -88M 5M -15M
depreciationAndAmortization 110M 116M 82M 93M 91M 93M 93M
deferredIncomeTax 44M -1 000 000 10M -25M 6M -51M 2M
stockBasedCompensation 0 16M 16M 18M 24M 17M 18M
changeInWorkingCapital 11M -100M 1 000 000 -92M -95M 88M -85M
accountsReceivables -92M -39M -8M -84M 10M -27M -44M
inventory -86M -120M -62M -14M -68M 2M -34M
accountsPayables 70M 188M 54M 21M -18M 110M 1 000 000
otherWorkingCapital 119M -129M 17M -15M -19M 3M -8M
otherNonCashItems 371M 35M 19M 11M 6M 7M 14M
netCashProvidedByOperatingActivities 41M 15M 48M -24M -56M 159M 27M
investmentsInPropertyPlantAndEquipment -67M -84M -30M -30M -37M -45M -54M
acquisitionsNet 1 000 000 -49M -1 861M 3M 25M 45M 0
purchasesOfInvestments -3M -4M -2M -3M -39M -47M -1 000 000
salesMaturitiesOfInvestments 6M 2M 4M 4M 12M 2M 6M
otherInvestingActivites 6M -172 313 7M -2M -25M -45M 0
netCashUsedForInvestingActivites -57M -135M -1 882M -28M -64M -90M -49M
debtRepayment -17M -7M -141M -7M -6M -7M 0
commonStockIssued 0 0 0 0 0 0 0
commonStockRepurchased 0 -1 000 000 -3M 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -5M 93M 1 955M 97M 97M 0 -109M
netCashUsedProvidedByFinancingActivities 12M 86M 1 811M 90M 91M -7M -109M
effectOfForexChangesOnCash -5M 8M -9M -4M 7M 21M -18M
netChangeInCash -9M -26M -32M 34M -22M 83M -149M
cashAtEndOfPeriod 325M 334M 360M 392M 358M 380M 297M
cashAtBeginningOfPeriod 334M 360M 392M 358M 380M 297M 446M
operatingCashFlow 41M 15M 48M -24M -56M 159M 27M
capitalExpenditure -67M -84M -30M -30M -37M -45M -54M
freeCashFlow -26M -69M 18M -54M -93M 114M -27M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-21 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-06 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-06-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-01 10:58 ET
Bausch + Lomb Announces First-Quarter 2024 Results
2024-04-29 11:00 ET
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
2024-04-25 12:30 ET
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
2024-04-18 11:00 ET
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
2024-04-15 16:00 ET
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
2024-03-27 11:00 ET
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
2024-02-28 13:00 ET
Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors
2024-02-21 11:58 ET
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance
2024-02-05 17:00 ET
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21
2024-01-08 11:59 ET
Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery
2024-01-03 14:00 ET
Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-15 11:59 ET
Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
2023-11-01 10:58 ET
Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance
2023-10-26 10:59 ET
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting
2023-10-16 16:00 ET
Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1
2023-10-04 10:59 ET
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting
2023-09-29 14:00 ET
Bausch + Lomb Completes Acquisition of XIIDRA®
2023-09-26 10:59 ET
Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States
2023-09-20 10:59 ET
Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners
2023-09-14 21:25 ET
Bausch + Lomb Announces Pricing of Senior Secured Notes Offering
2023-09-12 10:59 ET
Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States
2023-09-11 11:07 ET
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
2023-09-06 21:58 ET
Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
2023-09-06 10:59 ET
Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting
2023-08-29 11:00 ET
Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference
2023-08-24 11:00 ET
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®
2023-08-02 10:59 ET
Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook
2023-08-01 12:00 ET
Bausch + Lomb Solidifies Leadership Team
2023-07-11 11:00 ET
Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2
2023-07-06 11:00 ET
Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops
2023-06-30 12:00 ET
Bausch + Lomb Will Acquire XIIDRA®
2023-06-12 11:00 ET
Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10 in the United States
2023-06-08 11:00 ET
Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting
2023-06-06 11:00 ET
Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States
2023-06-05 11:00 ET
Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States
2023-06-01 11:00 ET
Bausch + Lomb Announces Key Leadership Changes
2023-05-18 17:56 ET
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease
2023-05-03 10:59 ET
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
2023-05-01 11:00 ET
Bausch + Lomb Releases Annual Environmental, Social and Governance Report
2023-04-26 11:00 ET
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
2023-04-25 11:00 ET
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results
2023-04-24 11:00 ET
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System
2023-04-20 11:00 ET
Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting
2023-04-18 11:00 ET
Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
2023-04-17 11:00 ET
Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3
2023-04-13 11:00 ET
Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform
2023-04-12 11:00 ET
Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
2023-03-22 11:00 ET
Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology
2023-02-22 11:59 ET
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
2023-02-15 11:58 ET
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
2023-02-07 12:00 ET
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
2023-02-01 12:00 ET
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
2023-01-23 12:00 ET
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
2023-01-17 22:09 ET
Bausch + Lomb Acquires AcuFocus, Inc.
2023-01-09 13:00 ET
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™
2023-01-09 12:00 ET
Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference
2023-01-05 12:00 ET
Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference
2023-01-04 12:00 ET
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology
2023-01-03 12:00 ET
Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month
2022-12-22 21:00 ET
Bausch + Lomb Amends CEO Separation Agreement
2022-12-13 12:00 ET
Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops
2022-12-12 12:00 ET
Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Win Gold for Most Environmentally Friendly Service of the Year from Best in Biz Awards
2022-11-29 14:15 ET
Bausch + Lomb's Biotrue® Hydration Plus Multi-Purpose Solution Receives Product of the Year Award from Business Intelligence Group's 2022 BIG Awards for Business
2022-11-15 12:00 ET
Bausch + Lomb Reports More Than 58 Million Units of Contact Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
2022-11-07 12:00 ET
Bausch + Lomb Announces Participation at the 5th Annual Evercore ISI HealthCONx Conference
2022-11-02 10:59 ET
Bausch + Lomb Announces Third-Quarter 2022 Results
2022-11-01 13:15 ET
Bausch + Lomb #LUMIFYEyeDance Challenge Wins 2022 Public Relations and Marketing Excellence Award for External Campaign of the Year from Business Intelligence Group
2022-10-24 11:00 ET
Bausch + Lomb Introduces Project Watson™ Health Care Products for Dogs
2022-10-18 11:00 ET
Bausch + Lomb Announces Presentation of Scientific Data and Analyses Evaluating Biotrue® Hydration Plus Multi-Purpose Solution at American Academy of Optometry Annual Meeting
2022-10-04 11:00 ET
Bausch + Lomb Will Release Third-Quarter 2022 Financial Results on November 2
2022-10-03 11:00 ET
Bausch + Lomb Introduces Enhanced Ocuvite® Adult 50+ Eye Vitamin Formulation With Vitamin D
2022-09-27 10:59 ET
Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress
2022-09-26 10:59 ET
Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting
2022-09-21 10:59 ET
Bausch + Lomb Announces Webinar for Eye Care Professionals on New AREDS2 Study Findings
2022-09-13 11:00 ET
First Annual Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on Age-related Macular Degeneration, a Leading Cause of Vision Loss for People 50+
2022-09-06 11:00 ET
Bausch + Lomb and Novaliq Announce U.S. FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)
2022-09-01 11:00 ET
Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments s.r.l. Intraocular Dyes
2022-08-29 11:00 ET
Bausch + Lomb Announces Participation at Upcoming Investor Conferences
2022-08-04 10:59 ET
Bausch + Lomb Announces Second-Quarter 2022 Results
2022-07-28 12:00 ET
Bausch + Lomb Launches the #LUMIFYEyeDance Challenge on TikTok
2022-07-28 11:00 ET
Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma
2022-07-26 10:59 ET
Bausch + Lomb Enrolls First Patient in LASIK Clinical Trial Evaluating Use of Technolas® TENEO™ Excimer Laser* for Vision Correction Surgery for Hyperopia with Astigmatism
2022-07-25 11:00 ET
Bausch + Lomb Will Release Second-Quarter 2022 Financial Results on August 4
2022-07-07 10:59 ET
Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane)
2022-07-06 10:59 ET
Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting
2022-06-23 20:51 ET
Bausch + Lomb Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors
2022-06-13 11:00 ET
Bausch + Lomb Announces the U.S. Launch of Revive™ Custom Soft Contact Lenses
2022-06-08 10:59 ET
Bausch + Lomb Announces First-Quarter 2022 Results and Provides 2022 Guidance
2022-06-06 11:00 ET
Bausch + Lomb Announces Scientific Data on Latest Biotrue® Products to be Presented at American Optometric Association's Optometry's Meeting
2022-06-02 12:00 ET
New Social Media Campaign From Bausch + Lomb Aims to Raise Awareness that Cataracts Don't Wait
2022-06-02 11:00 ET
Bausch + Lomb Announces the U.S. Launch of Biotrue® Hydration Plus Multi-Purpose Solution
2022-05-25 11:00 ET
Bausch + Lomb Will Release First-Quarter 2022 Financial Results on June 8
2022-05-24 10:59 ET
Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops
2022-05-16 23:17 ET
Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022
2022-05-13 11:00 ET
Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference
2022-05-12 10:59 ET
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis

SEC forms

Show financial reports only

SEC form 10
2024-05-01 16:47 ET
Bausch + Lomb Corporation published news for 2024 q1
SEC form 8
2024-05-01 07:02 ET
Bausch + Lomb Corporation published news for 2024 q1
SEC form 8
2024-05-01 07:02 ET
Bausch + Lomb Corporation reported for 2024 q1
SEC form 10
2024-05-01 00:00 ET
Bausch + Lomb Corporation published news for 2024 q1
SEC form 10
2024-02-21 16:55 ET
Bausch + Lomb Corporation published news for 2023 q4
SEC form 8
2024-02-21 07:00 ET
Bausch + Lomb Corporation published news for 2023 q4
SEC form 8
2024-02-21 07:00 ET
Bausch + Lomb Corporation reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
Bausch + Lomb Corporation published news for 2023 q4
SEC form 10
2023-11-01 17:03 ET
Bausch + Lomb Corporation published news for 2023 q3
SEC form 8
2023-11-01 07:02 ET
Bausch + Lomb Corporation reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Bausch + Lomb Corporation published news for 2023 q3
SEC form 10
2023-08-02 16:18 ET
Bausch + Lomb Corporation published news for 2023 q2
SEC form 6
2023-08-02 07:02 ET
Bausch + Lomb Corporation reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Bausch + Lomb Corporation published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Bausch + Lomb Corporation published news for 2023 q2
SEC form 6
2023-07-07 07:34 ET
Bausch + Lomb Corporation published news for 2023 q2
SEC form 6
2023-06-30 08:08 ET
Bausch + Lomb Corporation published news for 2023 q1
SEC form 6
2023-06-12 16:05 ET
Bausch + Lomb Corporation published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Bausch + Lomb Corporation published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Bausch + Lomb Corporation published news for 2023 q1
SEC form 10
2023-02-22 00:00 ET
Bausch + Lomb Corporation reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Bausch + Lomb Corporation reported for 2022 q4
SEC form 10
2022-11-02 00:00 ET
Bausch + Lomb Corporation reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Bausch + Lomb Corporation reported for 2022 q3
SEC form 10
2022-08-04 00:00 ET
Bausch + Lomb Corporation reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Bausch + Lomb Corporation reported for 2022 q2
SEC form 8
2022-06-08 00:00 ET
Bausch + Lomb Corporation published news for 2022 q1
SEC form 10
2022-06-08 00:00 ET
Bausch + Lomb Corporation reported for 2022 q1
SEC form 8
2022-05-17 00:00 ET
Bausch + Lomb Corporation reported for 2022 q1

SEDAR forms

Show financial reports only

SEDAR form
2023-05-03
BLCO published news for 2023 q2
SEDAR form
2023-02-22
BLCO published news for 2023 q1
SEDAR form
2023-02-22
BLCO published news for 2023 q1
SEDAR form
2023-02-22
BLCO published news for 2023 q1
SEDAR form
2022-11-02
BLCO published news for 2022 q4
SEDAR form
2022-08-04
BLCO published news for 2022 q3
SEDAR form
2022-06-08
BLCO published news for 2022 q2
SEDAR form
2022-05-16
BLCO published news for 2022 q2